Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Role of P2X7 receptor in angiotensin-II induced hypertension and cardiovascular injury
FY 2017-18
Summary
Seven and a half million people in Canada live with hypertension, which is a major risk factor for the development of heart disease and the single most important risk factor for stroke, both of which are leading causes of death worldwide. Over time, hypertension damages the body's blood vessels, causing them to become stiffer and thicker, and forcing the heart to work harder. Despite the vast array of medication, the prevalence of hypertension continues to increase worldwide and there is a lack of adequate treatment options for a large portion of the population. Inflammation and immunity act as protection in case of disturbances in the healthy functioning of the body, which is seen in hypertension. During the past several years, it has been shown that both the innate (non-specific) and the adaptive (specific) immune systems play a critical role in the development of hypertension. In hypertension and other inflammatory diseases, the initial activation of the immune system may be initiated by activation of the P2X7 receptor present both on immune cells and cells of the vessel walls. When stimulated, this receptor will activate the innate immune cells (monocytes/macrophages) triggering the release of pro-inflammatory mediators, which causes the activation of additional pro-inflammatory cells, as well as the activation of the adaptive immune cells (T lymphocytes). By investigating the role of the P2X7 receptor in the activation of the immune response during hypertension, we hope to identify new therapeutic targets for the treatment of hypertension and related cardiovascular diseases, thus contributing to improved outcomes for patients with high blood pressure and cardiovascular disease.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
386428
Name
Shokoples Brandon G
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Role of P2X7 receptor in angiotensin-II induced hypertension and cardiovascular injury
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adaptive Immunity; Angiotensin-Ii; Atp; Cardiovascular Diseases; Hypertension; Immune; Inflammation; Inflammosome; Innate Immunity; P2x7
Abstract
Seven and a half million people in Canada live with hypertension, which is a major risk factor for the development of heart disease and the single most important risk factor for stroke, both of which are leading causes of death worldwide. Over time, hypertension damages the body's blood vessels, causing them to become stiffer and thicker, and forcing the heart to work harder. Despite the vast array of medication, the prevalence of hypertension continues to increase worldwide and there is a lack of adequate treatment options for a large portion of the population. Inflammation and immunity act as protection in case of disturbances in the healthy functioning of the body, which is seen in hypertension. During the past several years, it has been shown that both the innate (non-specific) and the adaptive (specific) immune systems play a critical role in the development of hypertension. In hypertension and other inflammatory diseases, the initial activation of the immune system may be initiated by activation of the P2X7 receptor present both on immune cells and cells of the vessel walls. When stimulated, this receptor will activate the innate immune cells (monocytes/macrophages) triggering the release of pro-inflammatory mediators, which causes the activation of additional pro-inflammatory cells, as well as the activation of the adaptive immune cells (T lymphocytes). By investigating the role of the P2X7 receptor in the activation of the immune response during hypertension, we hope to identify new therapeutic targets for the treatment of hypertension and related cardiovascular diseases, thus contributing to improved outcomes for patients with high blood pressure and cardiovascular disease.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shokoples, Brandon G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~